I'm glad this article calls out the CLL drug ibrutinib. You hear a lot of people say "why aren't we making progress in treating cancer?". Well we are, ibrutinib is a great example.

The clinical trial data I looked at a couple year ago is a little fuzzy, but basically if you had CLL and the 17p deletion, your chance of being alive after 2 years was ~25% (using the standard of care before ibrutinib). In the ibrutinib clinical trial, 95%+ of 17p CLL patients were still alive after 2 years.

A massive jump forward in the treatment of cancer.